FATE – Fate Therapeutics, Inc.
Fate Therapeutics, Inc.FATE
$1.61Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $195,117,856.00
EPSttm : -1.03
Fate Therapeutics, Inc.
$1.61
9.32%$0.165
FATE — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
8.6
Margin Of Safety %
Put/Call OI Ratio
0.36
EPS Next Q Diff
-0.03
EPS Last/This Y
0.13
EPS This/Next Y
0.05
Price
1.6
Target Price
5.56
Analyst Recom
2.09
Performance Q
-36.31
Upside
-931.7%
Beta
2.68
Ticker: FATE
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | FATE | 2 | 0.18 | 0.40 | 6130 |
| 2026-10-14 | FATE | 1.94 | 0.18 | 0.06 | 6219 |
| 2026-10-15 | FATE | 1.93 | 0.17 | 0.00 | 6245 |
| 2026-10-16 | FATE | 1.78 | 0.17 | 0.00 | 6257 |
| 2026-10-19 | FATE | 1.87 | 0.19 | 0.33 | 5837 |
| 2026-10-20 | FATE | 2.06 | 0.19 | 4.53 | 5825 |
| 2026-10-21 | FATE | 2.08 | 0.20 | 1.46 | 5921 |
| 2026-10-22 | FATE | 2.105 | 0.21 | 2.13 | 6012 |
| 2026-10-23 | FATE | 2.11 | 0.20 | 4.94 | 6010 |
| 2026-10-26 | FATE | 2.05 | 0.20 | 3.46 | 5992 |
| 2026-10-27 | FATE | 2.07 | 0.21 | 17.80 | 6141 |
| 2026-10-28 | FATE | 2.17 | 0.22 | 0.76 | 6231 |
| 2026-10-29 | FATE | 2.18 | 0.24 | 1.34 | 6306 |
| 2026-10-30 | FATE | 2.09 | 0.24 | 0.76 | 6341 |
| 2026-11-02 | FATE | 2.03 | 0.24 | 5.59 | 6329 |
| 2026-11-03 | FATE | 2.05 | 0.24 | 0.00 | 6411 |
| 2026-11-04 | FATE | 2.1 | 0.24 | 20.00 | 6405 |
| 2026-11-05 | FATE | 1.86 | 0.24 | 51.00 | 6388 |
| 2026-11-06 | FATE | 1.84 | 0.23 | 0.49 | 6381 |
| 2026-11-09 | FATE | 1.94 | 0.23 | 10.94 | 6382 |
| 2026-11-10 | FATE | 1.77 | 0.35 | 42.57 | 7029 |
| 2026-11-11 | FATE | 1.605 | 0.36 | 0.42 | 7079 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | FATE | 2.00 | 5.6 | - | -1.02 |
| 2026-10-14 | FATE | 1.93 | 5.6 | - | -1.02 |
| 2026-10-15 | FATE | 1.93 | 5.6 | - | -1.02 |
| 2026-10-16 | FATE | 1.79 | 5.6 | - | -1.02 |
| 2026-10-19 | FATE | 1.87 | 5.6 | - | -1.02 |
| 2026-10-20 | FATE | 1.87 | 5.6 | - | -1.02 |
| 2026-10-21 | FATE | 2.05 | 5.6 | - | -1.02 |
| 2026-10-22 | FATE | 2.11 | 5.6 | - | -1.02 |
| 2026-10-23 | FATE | 2.10 | 5.6 | - | -1.02 |
| 2026-10-26 | FATE | 2.06 | 5.6 | - | -1.02 |
| 2026-10-27 | FATE | 2.06 | 5.6 | - | -1.02 |
| 2026-10-28 | FATE | 2.18 | 5.6 | - | -1.02 |
| 2026-10-29 | FATE | 2.18 | 5.6 | - | -1.02 |
| 2026-10-30 | FATE | 2.09 | 5.6 | - | -1.02 |
| 2026-11-02 | FATE | 2.03 | 5.6 | - | -1.02 |
| 2026-11-03 | FATE | 2.05 | 5.6 | - | -1.02 |
| 2026-11-04 | FATE | 2.10 | 5.6 | - | -1.02 |
| 2026-11-05 | FATE | 1.85 | 5.6 | - | -1.02 |
| 2026-11-06 | FATE | 1.84 | 0.0 | - | -1.02 |
| 2026-11-09 | FATE | 1.95 | 0.0 | - | -1.02 |
| 2026-11-10 | FATE | 1.77 | 0.0 | - | -1.02 |
| 2026-11-11 | FATE | 1.60 | 0.0 | - | -1.02 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | FATE | -2.39 | -1.87 | 9.42 |
| 2026-10-14 | FATE | -2.39 | -1.87 | 9.42 |
| 2026-10-15 | FATE | -2.39 | -1.87 | 9.42 |
| 2026-10-16 | FATE | -2.39 | -1.87 | 9.42 |
| 2026-10-19 | FATE | -2.39 | -2.02 | 9.42 |
| 2026-10-20 | FATE | -2.39 | -2.02 | 9.42 |
| 2026-10-21 | FATE | -2.39 | -2.02 | 9.42 |
| 2026-10-22 | FATE | -2.39 | -2.02 | 9.42 |
| 2026-10-23 | FATE | -2.39 | -2.02 | 9.42 |
| 2026-10-26 | FATE | -2.39 | -0.94 | 9.42 |
| 2026-10-27 | FATE | -2.39 | -0.94 | 9.30 |
| 2026-10-28 | FATE | -2.39 | -0.94 | 9.30 |
| 2026-10-29 | FATE | -2.39 | -0.94 | 9.30 |
| 2026-10-30 | FATE | -2.39 | -0.94 | 9.30 |
| 2026-11-02 | FATE | -2.39 | -1.07 | 9.30 |
| 2026-11-03 | FATE | -2.39 | -1.07 | 9.30 |
| 2026-11-05 | FATE | -2.51 | -1.07 | 9.30 |
| 2026-11-06 | FATE | -2.51 | -1.07 | 9.30 |
| 2026-11-09 | FATE | -2.47 | -1.78 | 9.16 |
| 2026-11-10 | FATE | -2.47 | -1.78 | 9.16 |
| 2026-11-11 | FATE | -2.47 | -1.78 | 8.60 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.25
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.28
Insider Transactions
-2.47
Institutional Transactions
-1.78
Beta
2.68
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
13
Growth Score
23
Sentiment Score
8
Actual DrawDown %
97.6
Max Drawdown 5-Year %
-98.9
Target Price
5.56
P/E
Forward P/E
PEG
P/S
41.08
P/B
1.47
P/Free Cash Flow
EPS
-1.03
Average EPS Est. Cur. Y
-1.02
EPS Next Y. (Est.)
-0.97
Target Price Estimates Raised
Target Price Estimates Lowered
1
Profit Margin
-2619.64
Relative Volume
1.81
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
FATE
Healthcare
$1.61
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
30.6
Range 1M
0.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
11.1%
EPS NY
-1.8%
52W%
28.7%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+245.3% upside
Upside
+245.3%
Quality
13
FATE — P/E HistoricalBiotechnology
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 161
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
FATE
Latest News
—
Caricamento notizie per FATE…
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading